Literature DB >> 22943198

Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients.

R Dellalibera-Joviliano1, E E Joviliano, J S Silva, P R B Evora.   

Abstract

Thromboangiitis obliterans (TAO) is a segmental inflammatory occlusive disorder that affects the arm and leg arteries of young smokers. The immune system seems to play a critical role in the aetiology of TAO; however, knowledge of the aspects involved in the progression of vascular tissue inflammation and, consequently, the evolution of this disease is still limited. This study was carried out to investigate the cytokine levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-4, IL-17 and IL-23 in the plasma of TAO patients presenting with acute clinical manifestations. The study included 20 TAO patients (n = 10 women; n = 10 men) aged 38-59 years under clinical follow-up, classified into two groups: (i) TAO former smokers (n = 11) and (ii) TAO active smokers (n = 9); the control groups included normal volunteer non-smokers (n = 10, active smokers (n = 10) and former smokers (n = 10). Patients' plasma samples were measured using the sandwich enzyme-linked immunosorbent assay. Statistical analyses were performed using the non-parametric Mann-Whitney U-test, with parameters significant at P < 0·05. The activities of all cytokines were different in groups of TAO patients when compared with normal controls, and decreased for control smokers. Increased levels of TNF-α, IL-1β, IL-4, IL-17 and IL-23 were significant in patients with TAO when compared to the controls (P < 0·005, all parameters). The results presented here indicate an increased production of cytokines in TAO, possibly contributing to the inflammatory response observed in the patients' vascular levels. In addition, the increased levels of IL-17 and IL-23 suggest that the disturbance of TAO is involved with mechanisms of autoimmunity. Thus, the discovery of IL-17 and its association with inflammation and autoimmune pathology has reshaped our viewpoint regarding the pathogenesis of TAO, which was based previously on the T helper type 1 (Th1)-Th2 paradigm.
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22943198      PMCID: PMC3444714          DOI: 10.1111/j.1365-2249.2012.04624.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

Review 1.  A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis.

Authors:  Brian Astry; Erin Harberts; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

2.  Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.

Authors:  Renata Dellalibera-Joviliano; Anna L B Jacob-Ferreira; Edwaldo Edner Joviliano; José E Tanus-Santos; Paulo R B Evora
Journal:  Vasc Med       Date:  2012-03-08       Impact factor: 3.239

3.  Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans.

Authors:  R Dellalibera-Joviliano; E E Joviliano; P R B Evora
Journal:  Scand J Immunol       Date:  2010-08       Impact factor: 3.487

4.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

5.  Current pathological and clinical aspects of Buerger's disease in Japan.

Authors:  Masayoshi Kobayashi; Naomichi Nishikimi; Kimihiro Komori
Journal:  Ann Vasc Surg       Date:  2006-01       Impact factor: 1.466

6.  The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease).

Authors:  J W Olin; J R Young; R A Graor; W F Ruschhaupt; J R Bartholomew
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

7.  Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience.

Authors:  T Sasajima; Y Kubo; M Inaba; K Goh; N Azuma
Journal:  Eur J Vasc Endovasc Surg       Date:  1997-02       Impact factor: 7.069

8.  Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans).

Authors:  M Kobayashi; M Ito; A Nakagawa; N Nishikimi; Y Nimura
Journal:  J Vasc Surg       Date:  1999-03       Impact factor: 4.268

9.  Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans.

Authors:  Krasimira Halacheva; Maya V Gulubova; Irena Manolova; Dimitar Petkov
Journal:  Acta Histochem       Date:  2002       Impact factor: 2.479

10.  The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat.

Authors:  Nicolas Manel; Derya Unutmaz; Dan R Littman
Journal:  Nat Immunol       Date:  2008-05-04       Impact factor: 25.606

View more
  8 in total

Review 1.  Buerger's disease: providing integrated care.

Authors:  Peter Klein-Weigel; Theresa Sophie Volz; Leonora Zange; Jutta Richter
Journal:  J Multidiscip Healthc       Date:  2016-10-12

Review 2.  Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature.

Authors:  Javier Narváez; Carmen García-Gómez; Lorenzo Álvarez; Pilar Santo; María Aparicio; María Pascual; Mercè López de Recalde; Helena Borrell; Joan M Nolla
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

3.  Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease).

Authors:  Jorge D Martin-Rufino; Francisco S Lozano; Alba M Redondo; Eva M Villaron; Raquel Rueda; Rafael Fernandez-Samos; Fermin Sanchez-Guijo
Journal:  Stem Cell Res Ther       Date:  2018-05-30       Impact factor: 6.832

4.  The Imbalance among Oxidative Biomarkers and Antioxidant Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease).

Authors:  Hiva Sharebiani; Bahare Fazeli; Rosanna Maniscalco; Daniela Ligi; Ferdinando Mannello
Journal:  J Clin Med       Date:  2020-04-07       Impact factor: 4.241

5.  Copy number gain of pro-inflammatory genes in patients with HBV-related acute-on-chronic liver failure.

Authors:  Fengming Sun; Wenting Tan; Yunjie Dan; Xiuhua Wang; Yanzhi Guo; Guohong Deng
Journal:  BMC Med Genomics       Date:  2020-12-01       Impact factor: 3.063

6.  The Association of HLA-A, B and DRB1 with Buerger's Disease.

Authors:  Abbas Shapouri-Moghaddam; Mojgan Mohammadi; Hamid Reza Rahimi; Habibolah Esmaeili; Mahmoud Mahmoudi; Mohammad-Hadi Saeed Modaghegh; Jalil Tavakol Afshari
Journal:  Rep Biochem Mol Biol       Date:  2019-07

7.  Effect of revascularization on IL-6 and TNF-α in patients with thromboangiitis obliterans.

Authors:  Shifeng Wu; Xin Sun; Wei Wu; Dazhi Shi; Tao Jiang
Journal:  Exp Ther Med       Date:  2018-02-20       Impact factor: 2.447

8.  Assessment of T helper 17-associated cytokines in thromboangiitis obliterans.

Authors:  Shayan Keramat; Mohammad Hadi Sadeghian; Mohammad Reza Keramati; Bahare Fazeli
Journal:  J Inflamm Res       Date:  2019-09-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.